



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Naltrexone + bupropion](#) > [Printer-friendly PDF](#)

Naltrexone + bupropion

Trade Name:

Contrave

Manufacturer/Distributor:

Valeant Canada LP

Classification:

Anorexigenic agents

ATC Class:

A08AA62: bupropion and naltrexone

Status:

active

Notice of Compliance (yyyy/mm/dd):

2018/02/13

Date Marketed in Canada (yyyy/mm/dd):

2018/02/13

Presentation:

Tablet, extended release: naltrexone 8 mg, bupropion 90 mg. DIN: 02472945

Comments:

For use as an adjunct to a calorie reduced diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia).

Keywords: bupropion
naltrexone
obesity

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:

Search Terms:

Apply

A (32) | B (18) | C (20) | D (33) | E (32) | F (11) | G (7) | H (9) | I (21) | K (1) | L (23) | M (12) | N (6) | O (10) | P (25) | R (12) | S (21) | T (26) | U (2) | V (12) | Z (4)

| <u>Generic Name</u> | <u>Common Trade Name(s)</u> | <u>Classification</u> | <u>Date Marketed in Canada (yyyy/mm/dd)</u> |
|--|-----------------------------|---|---|
| <u>Abatacept</u> | Orencia | Co-stimulation modulator for rheumatoid arthritis | 2006/09 |
| <u>Abiraterone</u> | Zytiga | Androgen biosynthesis inhibitor | 2011/08/08 |
| <u>Acamprosate</u> | Campral | Alcohol abstinence aid | 2007/03 |
| <u>Acclidinium + formoterol</u> | Duaklir Genuair | Bronchodilator combination - LAMA plus LABA | 2015/07/09 |
| <u>Acclidinium bromide</u> | Tudorza Genuair | Bronchodilator | 2013-09 |
| <u>Adapalene + benzoyl peroxide</u> | Tactuo | Acne therapy | 2011/04 |
| <u>Adefovir dipivoxil</u> | Hepsera | Antiviral agent | 2006/10 |
| <u>Afatinib</u> | Giotrif | Protein kinase inhibitor | 2014/05/28 |
| <u>Albiglutide</u> | Eperzan | Antihyperglycemic agent | 2016/02/19 |
| <u>Alendronate</u> | Fosamax | Bone resorption inhibitor | 2011/03 |
| <u>Alglucosidase alfa</u> | Myozyme | Enzyme replacement therapy | 2007/04 |
| <u>Aliskiren and hydrochlorothiazide</u> | Rasilez HCT | Renin inhibitor and diuretic | 2009/09 |
| <u>Alitretinoin</u> | Toctino | Immunomodulator, antiinflammatory agent | 2010/10/19 |
| <u>Alogliptin</u> | Nesina | Oral antihyperglycemic agent | 2014/10/08 |
| <u>Alogliptin + metformin</u> | Kazano | Oral antihyperglycemic agent | 2014/10/08 |
| <u>Aluminum chloride hexahydrate</u> | Hydrosal gel | Antiperspirant | |
| <u>Aminophylline</u> | Phyllocontin | Bronchodilator | 2010 |
| <u>Apixaban</u> | Eliquis | Anticoagulant | 2012/03 |

| <u>Generic Name</u> | <u>Common Trade Name(s)</u> | <u>Classification</u> | <u>Date Marketed in Canada (yyyy/mm/dd)</u> |
|---|-----------------------------|---|---|
| <u>Apomorphine</u> | Movapo | Nonergot-derivative dopamine receptor agonist | 2018/04/xx |
| <u>Apremilast</u> | Otezla | Immunosuppressant agent | 2014/12/08 |
| <u>Aripiprazole</u> | Abilify | Antipsychotic agent | 2009/07/03 |
| <u>ASA + Meprobamate + Codeine + Caffeine</u> | 282 MEP | Narcotic analgesic | |
| <u>Asenapine</u> | Saphris | Atypical antipsychotic | 2012/03/16 |
| <u>Asunaprevir</u> | Sunvepra | Antiviral agent | 2016/04/22 |
| <u>Avelumab</u> | Bavencio | Antineoplastic agent | 2017/12/18 |
| <u>Axitinib</u> | Inlyta | Anti-tumor agent | 2012/09 |
| <u>Azacitidine</u> | Vidaza | Antineoplastic agent | 2009/12/07 |
| <u>Azelastine + fluticasone</u> | Dymista | Antihistamine and corticosteroid agent | 2015/10/22 |
| <u>Azilsartan</u> | Edarbi | Antihypertensive agent | 2013/03/27 |
| <u>Azilsartan + chlorthalidone</u> | Edarbyclor | Antihypertensive agent | 2013/03/27 |
| <u>Azithromycin dihydrate</u> | Zmax SR | Antibiotic | 2010/10/29 |
| <u>Aztreonam</u> | Cayston | Antibacterial | 2009/11/11 |
| <u>Baricitinib</u> | Olumiant | Immunosuppressant | 2018/08/17 |
| <u>Belimumab</u> | Benlysta | Immunosuppressant | 2011/10/01 |
| <u>Bendamustine</u> | Treanda | Antineoplastic agent | 2012/09/12 |
| <u>Benralizumab</u> | Fasenra | Respiratory agent | 2018/03/28 |

1 [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [next](#) [?](#) [last](#) [»](#)

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2019-08-25 20:34): <http://www.dpic.org/druglisting/naltrexone-bupropion>